On July 5th, 2024, Harbin Gloria Pharmaceuticals (002437.SZ) accepted a specific survey and was asked about the market competitiveness and barriers of multiple vitamin (12) injections. The company replied that currently, there are only two companies selling this product in the market, and the market share of multiple vitamin (12) injections by Pude Pharmaceutical exceeds 80%. The market for this product is large and the difficulty of imitation is high. It is expected that the market structure will be relatively stable in the next 2-3 years.
誉衡药业(002437.SZ)：普德药业注射用多种维生素(12)的市场占有率达80%以上
Harbin Gloria Pharmaceuticals (002437.SZ): Holds a market share of over 80% for injectable multivitamins (12) by Pude Pharmaceutical.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.